A Phase 3 interventional study of Live donor uterus transplantation and Deceased donor uterus transplantation in Mayer Rokitansky Kuster Hauser Syndrome, Mullerian Aplasia and Uterus; Absence, Congenital, sponsored by Institute for Clinical and Experimental Medicine. Recruiting at 1 site in Czechia. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-02-27.
Sponsored by Institute for Clinical and Experimental Medicine · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Uterus transplantation (UTx) is the only causative treatment for congenital or acquired uterus absence. Individual cases of UTx from a live donor (LD UTx) with healthy child birth performed so far showed favourable outcomes. The present study will include both LD UTx and UTx from deceased donors after brain death (DBD UTx). The aim is treatment of uterine infertility by UTx. It is is an ethically justifiable life-promoting transplantation. Twenty UTx will be performed in 2 parallel arms: 10 LD UTx and 10 DBD UTx. Immunosuppression will be administered. Phases of the UTx procedure are: in vitro fertilization - cryopreservation of embryos - uterus retrieval - UTx - follow up - embryo transfer - pregnancy - child birth - later graft hysterectomy - life long follow up. Introduction of UTx into clinical practice may enable women with uterine infertility to have their own children.
Introduction: Uterus transplantation (UTx) is the only causative treatment for congenital or acquired uterus absence, i.e. absolute uterine factor infertility (AUFI). Feasibility of uterus transplantation from o live donor and possibility of healthy child birth have been proven in previous clinical study in Sweden. The present study is supposed to extend the swedish experience by including UTx from both live donors and from deceased donors after brain death.
Aim: Treatment of absolute uterine factor infertility that has no other therapy option by uterus transplantation. Extending basic knowledge on UTx. Possible introduction of UTx into clinical practice.
Indications: UTx can be offered to patients with congenital uterus absence - aplasia uteri et vaginae, also called Mullerian aplasia or Rokitansky-Mayer-Kuster-Hauser syndrome (RMKH), in whom previous neo-vagina was created. UTx can be performed also in women with acquired uterus absence on the basis of previous hysterectomy e.g. for myomas, endometriosis, post-partum bleeding, cervical cancer, uterus malformations or intrauterine adhesions. Ovarian function must be preserved and stable male partner is required for in vitro fertilization (IVF).
Ethics: Uterus retrieval from a deceased brain-dead donor does not endanger retrieval of other life-saving organs. Live donor does not loose a vitally important organ. The only alternative is adoption of a child. Surrogacy is illegal in many european countries. UTx is the only causative treatment of AUFI. It is is an ethically justifiable life-promoting transplantation. UTx improves quality of live of both the recipient and the live donor by giving an opportunity to have an own child. Board certification for this study was obtained from the Ministry of Health of the Czech Republic and from the local Ethics Committee.
Methods: Twenty UTx will be performed in total in 2 parallel arms: 10 UTx from a live donor (LD UTx) and 10 UTx from a deceased brain-dead donor (DBD UTx). Patients who have no suitable live donor will be wait-listed for a deceased donor. Compatible blood group and negative cross-match test is required. AB0 incompatible or pair exchange transplantations are also possible. Donors and recipients will be examined by clinical, laboratory and imaging methods. All diagnostic and therapeutic procedures will be performed according to a protocol. Risk and benefit will be assessed by a multi-disciplinary team. Informed consent will be signed. Time period between UTx and embryo transfer is supposed to be about 1 year depending on condition of the recipient and the graft, e.g. level of immunosuppression, rejection or infection episodes. Adverse events will be monitored and addressed. Number of possible pregnancies and child births is estimated to be up to 2. The uterus graft will be removed in the end. Overall time interval of keeping the uterus graft in situ and exposure to immunosuppressive therapy is estimated to be up to 5 years.
Immunosuppression: Induction immunosuppression is based on thymoglobuline and corticosteroids. Maintenance immunosuppression is based on tacrolimus, mycophenolate and corticosteroids. Temporary anti-infective prophylaxis will be administered. Minimalization of immunosuppression is needed before pregnancy (monotherapy with tacrolimus). Protocol cervix biopsies to look for possible rejection will be performed. Immunosuppression will be discontinued after graft hysterectomy.
Phases of the UTx procedure: in vitro fertilization (IVF phase I) - cryopreservation of embryos - uterus retrieval from a live donor or from a deceased donor - orthotopic uterus transplantation with open technique - follow up period - embryo transfer (IVF phase II) - pregnancy - child birth via Cesarian section - later graft hysterectomy - life long follow up.
Merit: Individual cases of uterus transplantation performed so far showed favourable outcomes. Introduction of UTx into clinical practice may enable women with uterine infertility to have their own children.
20 studies on the registry are indexed under Mullerian aplasia; 11 are open to participants now.
This study's planned enrollment of 20 is close to the median of 20 across 13 interventional studies indexed under Mullerian aplasia.
Browse Mullerian aplasia studies →Institute for Clinical and Experimental Medicine is the lead sponsor of 60 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for UTx recipient:
Exclusion Criteria for UTx recipient:
Inclusion Criteria for a live uterus donor:
Exclusion Criteria for a live uterus donor:
Inclusion Criteria for a deceased brain-dead uterus donor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
Procedure: Live donor uterus transplantation · Drug: Tacrolimus
Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
Procedure: Deceased donor uterus transplantation · Drug: Tacrolimus
Transplantation of uterus from a living donor.
Transplantation of uterus from a deceased brain-dead donor.
Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
Also known as: FK506
Efficacy of uterus transplantation.
Number of successful uterus transplantations and healthy child births. Treatment of absolute uterine factor infertility that has no other therapy option by uterus transplantation that includes in vitro fertilization and cryopreservation, uterus transplantation from a live donor or from a deceased donor, graft survival on immunosuppression, embryo transfer, pregnancy and child birth, final graft hysterectomy.
Time frame: Until 10 live donor and 10 deceased donor uterus transplants have been performed plus approximately 5 years.
Comparison of efficacy of uterus transplantation from live donors versus deceased donors.
Number of successful uterus transplantations and healthy child births from live donors versus deceased donors.
Time frame: Until 10 live donor and 10 deceased donor uterus transplants have been performed plus approximately 5 years.
Rate of adverse events after uterus transplantation
Number of recipients of uterus transplantation with adverse events.
Time frame: Until 10 live donor and 10 deceased donor uterus transplants have been performed plus approximately 5 years.
Rate of adverse events after live uterus donation
Number of live donor participants after uterus retrieval with adverse events.
Time frame: Until 10 live donor transplants have been performed plus approximately 5 years.
Rate of adverse events during pregnancy and child birth after uterus transplantation
Number of children conceived and born from transplanted uterus with adverse events.
Time frame: Until 10 live donor and 10 deceased donor uterus transplants have been performed plus approximately 5 years.
Verification of technique of uterus retrieval
Verification of surgical technique of uterus retrieval from a live donor and from a deceased donor.
Time frame: Until 10 live donor and 10 deceased donor uterus transplants have been performed plus approximately 5 years.
Plan to share: Undecided
Started Oct 2015 (actual). Primary completion is estimated for Dec 2020, 62 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute for Clinical and Experimental Medicine